Hola,
Are you new here?

LUMIBOR

financed

ILLUMINATING ROUTES TO 3D ORGANOBORON MOLECULES

With a steadily growing, aging population, there is significant strain on the pharmaceutical sector to produce state of the art therapeutics for societal needs whilst respecting the finite resources provided by the environment. Pr... see more

31/12/2029

MPG

1M€

Project Budget: 1M€

Project leader

MAXPLANCKGESELLSCHAFT ZUR FORDERUNG DER WISSE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Financing granted El organismo HORIZON EUROPE notifico la concesión del proyecto The day 2025-01-01

ERC-2024-STG: ERC STARTING GRANTS Scope:Objectives

I+D

Cerrada does 1 year

0% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

MPG

Leader

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 59 months Date Start: 2025-01-01
End date: 2029-12-31

Project leader

MAXPLANCKGESELLSCHAFT ZUR FORDERUNG DER WISSE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 1M€

participation deadline Sin fecha límite de participación.

Project description With a steadily growing, aging population, there is significant strain on the pharmaceutical sector to produce state of the art therapeutics for societal needs whilst respecting the finite resources provided by the environment. Prominent advances in drug design are reliant on chemical synthesis platforms allowing the efficient exploration of chemical space to discover next generation functional molecules. As a result, innovation is currently limited by the practical implementation of enabling methods, which often becomes the rate limiting factor in cutting-edge research: this is more pronounced when translating academic research to industrial settings. The current renaissance of organic photochemistry and light-driven processes in a broader sense provide an opportunity to reconcile the growing demand for new functional molecules with consideration of sustainability and atom economy. Inspired by the importance of organoboron motifs in medicinal chemistry, this EU action “LUMIBOR” will harness the untapped potential of boron hybridization and boron ligand design to unlock new excited state reactivity paradigms and thereby facilitate the discovery of new methods to access achiral and chiral 3D organoboron scaffolds. LUMIBOR will create a structural platform to utilize boron hybridization in the development of next generation light-enabled ACTIVATION methods. Understanding the correlation between hybridization and parameters such as excited state energy and adjacent bond dissociation energy will allow access to synthetically versatile, high-energy intermediates such as α-boryl radicals and the triplet excited state. Strategic control over boron hybridization will also be utilized to regulate REACTIVITY, by influencing radical philicty, spin density, and excited state lifetimes among other parameters. Collectively, LUMIBOR will create expansive guidelines to expand the synthesis arsenal by developing novel platforms to construct desirable 3D organoboron molecules.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers